---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-054758"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2023-07-05T23:59:59+00:00"
generated_at: "2026-06-13T12:44:13.069536+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Longeveron appoints Dr. Nataliya Agafonova as CMO, effective July 1, 2023

## Summary
- Dr. Agafonova replaces Dr. K. Chris Min, who stepped down as CMO on June 30, 2023.
- She will lead global clinical development and regulatory strategy.
- Agafonova previously served as Clinical Development Lead at Otsuka Pharmaceutical and Bristol-Myers Squibb.
- A consulting agreement with hourly cash fee is in place until full-time employment begins on or about July 24, 2023.

## SEC filing metadata
- accession: 0001213900-23-054758
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2023-07-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/0001213900-23-054758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/ea181311-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-054758
- JSON: https://secwatch.observer/filing/0001213900-23-054758.json
- Plain text: https://secwatch.observer/filing/0001213900-23-054758.txt

## Key facts
- Executive change
  K. Chris Min departed as Chief Medical Officer at Longeveron Inc..
  - Action: stepped down
  - Role: Chief Medical Officer
  source text: Dr. K. Chris Min, the Company’s prior CMO, stepped down effective June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/0001213900-23-054758-index.htm
- Executive change
  Nataliya Agafonova was appointed as Chief Medical Officer at Longeveron Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Longeveron Inc. (“Longeveron” or the “Company”) has announced the appointment of Dr. Nataliya Agafonova M.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (“CMO”), effective July 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/0001213900-23-054758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.